Company Statement:Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), together with its subsidiaries (including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer. Coeptis was founded in 2017 and is headquartered in Wexford, PA.
Tuesday, 15 November 2022
|Intrinsic Price ($)||7.89|
|Value Range Low ($)||7.69|
|Value Range High ($)||8.09|
|Implied EV (m)||225.44|
|Close Price ($)||2.17|
|Net Debt (Cash) (m)||-1.82|
|52 Wk Hi||21.42|
|52 Wk Lo||2.00|
(Net Cash) /Shareholder
Healthcare Sector Research
Nasdaq Market Index
+44 20 7419 7928
Coeptis Therapeutics Inc. (NASDAQ: COEP) is a pre-clinical stage biopharmaceutical Corp focused on fighting cancer via a pipeline of potentially novel products targeting CD38+ related unmet need and solid tumor cancers. The up list to Nasdaq via the SPAC Bull Horn Holdings (BHSE) is a key milestone leaving COEP with 19,516,839 shares in issue, better liquidity and greater access to capital needed to advance its pipeline. We assess that there are multiple value drivers within COEP, including its two lead candidates (GEAR-NK and CD38+-Diagnostic) along with its IP rights to its solid tumor targeting SNAP-CAR platform (‘universal wrench’)…To read more download note
We have modelled 3 NPVs for Coeptis Therapeutics, based upon its two core therapies and single diagnostics product. SNAP-CAR accounts for 48% of our total Coeptis Therapeutics NPV.
Coeptis Therapeutics Inc. (NASDAQ: COEP) is a biotech company fighting cancer using novel approaches and combinations (‘universal wrench’ technology platform). COEP’s innovative oncology cell therapy platforms include (CD38-GEAR-NK), an in vitro diagnostic (CD38-Diagnostic) targeting CD38+-related cancers (including unmet need) and SNAP-CAR ‘universal wrench’ for solid tumors – a pipeline of early-stage buyout candidates.
Large addressable market opportunity – CD38-GEAR-NK first indication target is expected to be multiple myeloma (MM). Value estimates for the MM market vary, however central tendency is around US$ 17bn YE18/19A with estimates running as high as ~30bn YE26E (e.g., DelveInsight, Fortune Business Insights).
Rights to CAR-T technologies (‘universal wrench’) adds future value – COEP has exclusive rights to the SNAP-CAR (chimeric antigen receptor T cell) technology to broaden COEP’s therapy portfolio to include solid tumors. COEP plans, initially, to target breast cancer and ovarian cancer with its CAR-T therapy…To read more download note
Coeptis Therapeutics’ strategy revolves around developing and expanding its product portfolio with an eye toward licensing and partnership with large cap pharma. COEP intends to expand its portfolio by seeking strategic partners which have novel, early-stage, and preclinical assets in a variety of therapeutic areas, including oncology and autoimmune disease.
Collaborations for Product Development: COEP has partnered with VyGen-Bio Inc to co-develop two early-stage product candidates and with the University of Pittsburgh, which gives COEP the option to license three CAR-T technologies. …To read more download note
Coeptis Therapeutics Inc. Financials 2028E – 2031E
Revenue (m) vs EBITDA (m) 2028E
Revenue (m) vs EBITDA (m) 2029E
Revenue(m) vs EBITDA (m) 2030E
Revenue (m) vs EBITDA (m) 2031E
Coeptis Therapeutics Inc. Catalysts
➢ Research news
➢ Positive pre-clinical results
➢ Licensing announcements
➢ Initiation of IND studies for SNAP-CAR
➢ Initiation of IND studies forand GEAR-NK